ORIC Pharmaceuticals, Inc. (ORIC) News
Follow ORIC Pharmaceuticals, Inc. (ORIC) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 12 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
ORIC Posts $0.44 Loss; Citi Raises Target, BTIG Keeps Buy
EQUITY | Nov 18, 2026, 08:01 AM UTC
M
Oric Reports Enozertinib Phase 1b Results, Plans Phase 3 in 2027
Oric reported systemic and intracranial activity for enozertinib in Phase 1b and plans a global Phase 3 trial in the first half of 2027.
EARNINGS | Oct 23, 2026, 12:03 PM UTC
L
Oric Pharmaceuticals Initiated at Buy by BTIG
Ratings actions from Benzinga
NEWS | Sep 23, 2026, 10:46 AM UTC
L
BTIG initiates coverage of ORIC Pharmaceuticals with Buy rating, $26 price target
BTIG initiated coverage on ORIC Pharmaceuticals's stock with a rating of Buy and a price target of $26.00.The price target implies an upside of 92.6% from the Sep 22 close of $13.50.Key takeaways from the analyst noteStr
EQUITY | Sep 23, 2026, 10:36 AM UTC
L
ORIC: Advancing late-stage cancer programs with strong safety profiles and robust funding through 2028
The company is advancing two late-stage oncology programs: rinzimetostat for prostate cancer, with a phase III trial underway and strong safety differentiation, and enozertinib for lung cancer, targeting brain metastases
NEWS | Sep 15, 2026, 03:24 PM UTC
L
ORIC: Advancing late-stage cancer programs with strong safety differentiation and robust financial runway
The company is advancing two late-stage oncology programs: rinzimetostat for prostate cancer, now in Phase III, and enozertinib for lung cancer, with a key data update expected soon. Differentiation is driven by safety a
NEWS | Sep 15, 2026, 02:56 PM UTC
L
ORIC: Late-stage cancer programs advance with strong funding, key data, and safety differentiation ahead
Two late-stage oncology programs are advancing, with rinzimetastat in phase III for prostate cancer and enozertinib targeting lung cancer. Key differentiators include safety and potential resistance advantages, with majo
EQUITY | Sep 09, 2026, 07:51 PM UTC
L
ORIC: Advancing late-stage cancer therapies with strong efficacy, safety, and major market potential
Two late-stage oncology programs, rinzimetostat and enozertinib, are advancing through pivotal trials targeting high unmet needs in prostate cancer and NSCLC, respectively. Both show strong efficacy, safety, and blockbus
EQUITY | Sep 09, 2026, 12:49 PM UTC
L
ORIC - ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC - ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
EQUITY | Sep 04, 2026, 08:30 PM UTC
L
ORIC - ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
ORIC - ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
EQUITY | Sep 02, 2026, 08:05 PM UTC
L
ORIC - ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates
ORIC - ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates
EARNINGS | Aug 03, 2026, 08:07 PM UTC
L
ORIC oric® Pharmaceuticals announces initiation of himalayas-1 phase 3 trial in mcrpc evaluating rinzimetostat in combination with nubeqa® (
ORIC oric® Pharmaceuticals announces initiation of himalayas-1 phase 3 trial in mcrpc evaluating rinzimetostat in combination with nubeqa® (darolutamide), supported by clinical collaboration with Bayer
EQUITY | Jul 14, 2026, 08:05 PM UTC